MorphoSys Reaches Seventh Clinical Milestone in 2010
CTA Filing Takes Company Beyond Original Guidance of 6 Clinical Milestones in 2010
MorphoSys AG announced that it has received a clinical milestone payment from Centocor Ortho Biotech Inc. in connection with the regulatory filing of a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases. This was the seventh clinical milestone for MorphoSys in 2010.
"The seventh clinical milestone with partners in 2010 surpasses our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news marks another milestone for the HuCAL platform, clearly illustrating the success of this technology."
MorphoSys's clinical pipeline now comprises nine partnered programs in Phase 1 and five in Phase 2 development as well as the Company's proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
University_of_South_Florida_College_of_Medicine
Biotage acquires Argonaut Technologies Consumable Division
Galapagos and Allergan enter drug discovery collaboration
Definiens and BioImage Announce Collaboration for High-Content Screening (HCS) Applications
Enzo Life Sciences Launches New Advanced Amplification Technology For Gene Expression Analysis Studies - Changes Paradigm of Gene Expression Microarray Analysis And Overcomes Limitations of Standard Methods
Covagen and Roche start collaboration
